CLEC1B Antibody - #DF14376

(1)   (4)  
Product: CLEC1B Antibody
Catalog: DF14376
Description: Rabbit polyclonal antibody to CLEC1B
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 27kD(Calculated).
Uniprot: Q9P126

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
CLEC1B Antibody detects endogenous levels of total CLEC1B.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

1810061I13Rik; C type lectin domain family 1 member B; C type lectin like receptor 2; C-type lectin domain family 1 member B; C-type lectin domain family 1, member B; C-type lectin-like receptor 2; C-type lectin-like receptor-2; CLC1B_HUMAN; CLEC 2; CLEC 2B; CLEC-2; CLEC1B; CLEC2; CLEC2B; PRO1384; QDED721;

Immunogens

Immunogen:

A synthesized peptide derived from Human CLEC1B.

Uniprot:

Q9P126(CLC1B_HUMAN) >>Visit HPA database.

Gene(ID):
CLEC1B(51266)
Expression:
Q9P126 CLC1B_HUMAN:

Expressed preferentially in the liver. Also expressed in immune cells of myeloid origin and on the surface of platelets.

Sequence:
MQDEDGYITLNIKTRKPALISVGSASSSWWRVMALILLILCVGMVVGLVALGIWSVMQRNYLQGENENRTGTLQQLAKRFCQYVVKQSELKGTFKGHKCSPCDTNWRYYGDSCYGFFRHNLTWEESKQYCTDMNATLLKIDNRNIVEYIKARTHLIRWVGLSRQKSNEVWKWEDGSVISENMFEFLEDGKGNMNCAYFHNGKMHPTFCENKHYLMCERKAGMTKVDQLP

Research Backgrounds

Function:

C-type lectin-like receptor that functions as a platelet receptor for the lymphatic endothelial marker, PDPN. After ligand activation, signals via sequential activation of SRC and SYK tyrosine kinases leading to activation of PLCG2.

(Microbial infection) Acts as a receptor for the platelet-aggregating snake venom protein rhodocytin. Rhodocytin binding leads to tyrosine phosphorylation and this promotes the binding of spleen tyrosine kinase (SYK) and initiation of downstream tyrosine phosphorylation events and activation of PLCG2.

(Microbial infection) Acts as an attachment factor for Human immunodeficiency virus type 1 (HIV-1) and facilitates its capture by platelets.

PTMs:

Glycosylated.

Phosphorylated on tyrosine residue in response to rhodocytin binding.

Subcellular Location:

Membrane>Single-pass type II membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed preferentially in the liver. Also expressed in immune cells of myeloid origin and on the surface of platelets.

Subunit Structure:

Homodimer. Interacts (via cytoplasmic domain) with RACK1; promotes CLEC1B ubiquitination and proteasome-mediated degradation. Interacts (dimer) with SYK (via SH2 domains). Interacts with PDPN; the interaction is independent of CLEC1B glycosylation and activates CLEC1B.

References

1). Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma. Cancer Cell International, 2023 (PubMed: 37308868) [IF=5.8]

Application: WB    Species: Human    Sample: HCC cells

Fig. 8 Expression validation of CLEC1B in HCC cells. (A, B) RT-qPCR (A) and western blot (B) detection of CLEC1B expression levels in HCC and normal hepatic liver cells. (C) Representative images of CLEC1B immunohistochemical staining of paired HCC and adjacent normal tissues. (D) Histogram shows the quantification data of immunohistochemical staining. (E) Protein expression of CLEC1B in SMMC-7721 plvx-neo and SMMC-7721 CLEC1B-neo cells. (F) Cell viability of SMMC-7721 plvx-neo and SMMC-7721 CLEC1B-neo upon sorafenib administration. (G) Flow cytometric analysis of apoptosis distribution after sorafenib treatment in SMMC-7721 cells, and the quantification data were shown on the right.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.